About our company

Neurophyxia was founded in 2008 and is headquartered in ’s-Hertogenbosch, the Netherlands. The company has developed a novel neuroprotectant from early preclinical phase upto current Phase IIb/III Clinical Development, thanks to its dedicated academic team,  backed-up by strong business and investment partners.

Neurophyxia is developing 2-iminobiotin (2-IB) for the treatment of cerebral hypoxie ischemia and subsequent reperfusion injury following Stroke, Cardiac Arrest and Birth Asphyxia. See for more information neuroprotection.